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Summary
Background Epilepsy is a heterogeneous disorder, with outcomes ranging from immediate remission after taking a 
ﬁ rst antiepileptic drug to frequent unremitting seizures with multiple treatment failures. Few prognostic models 
enable prediction of outcome; we therefore aimed to use data from the SANAD study to predict outcome overall and 
for patients receiving speciﬁ c treatments.
Methods The SANAD study was a randomised controlled trial in which standard antiepileptic drugs were compared 
with new treatments. Arm A included patients for whom carbamazepine was considered the ﬁ rst-line treatment, 
most of whom were newly diagnosed with focal epilepsy. Patients were randomly assigned to receive carba mazepine, 
gabapentin, lamotrigine, oxcarbazepine, or topiramate. Outcomes were time to treatment failure overall, because of 
inadequate seizure control, and because of adverse events, and time to 12 months of remission from seizures. In this 
post-hoc study we used regression multivariable modelling to investigate how clinical factors aﬀ ect the probability of 
treatment failure and the probability of achieving 12 months of remission.
Findings For time to treatment failure, we identiﬁ ed several signiﬁ cant risk factors: sex (male vs female, hazard ratio 
[HR] 0·86, 95% CI 0·75–0·99), treatment history (taking non-SANAD antiepileptic drugs [other than those listed 
above] vs treatment naive, 1·27, 1·05–1·53), age (eg, older than 71 years vs 10 years or younger, 0·68, 0·51–0·91), total 
number of seizures (eg, four to 11 seizures vs two or fewer, 1·08, 1·05–1·11), electroencephalogram results (epileptiform 
abnormality vs normal, 1·26, 1·07–1·50), seizure type (eg, secondary generalised vs simple or complex partial only, 
0·78, 0·66–0·91), site of onset (not localised vs temporal lobe, 1·25, 1·06–1·47), and treatment (lamotrigine vs 
carbamazepine, 0·76, 0·61–0·95). Signiﬁ cant factors for time to 12 months of remission were sex (male vs female, 
1·19, 1·05–1·35), treatment history (taking a non-SANAD antiepileptic drug vs treatment naive, 0·64, 0·52–0·78), age 
(eg, older than 71 years vs 10 years or younger, 1·60, 1·26–2·03), time from ﬁ rst seizure (60–239 months vs ≥2 months, 
1·14, 1·01–1·29; >240 months vs ≤2 months, 1·39, 1·04–1·86), neurological insult (presentv absent, 0·75, 0·61–0·93), 
total number of seizures before randomisation (eg, four to 11 vs two or fewer, 0·87, 0·85–0·90), and treatment 
(gabapentin vs carbamazepine, 0·71, 0·59–0·86; topiramate vs carbamazepine, 0·81, 0·68–0·98).
Interpretation We present a thorough investigation of prognostic factors from a large randomised controlled trial in 
patients starting antiepileptic monotherapy. If validated, our models could aid in individual patient risk stratiﬁ cation 
and the design and analysis of epilepsy trials.
Funding National Institute for Health Research (UK).
Introduction
Few epilepsy trials have been designed to be pragmatic, 
to recruit a broad heterogeneous population repre-
sentative of clinical practice, and to provide data that will 
inform everyday decision making. Arm A of the Standard 
and New Antiepileptic Drug (SANAD) trial1 recruited 
1721 patients for whom clinicians considered 
carbamazepine to be the ﬁ rst-line standard treatment, 
89% of whom had a focal epilepsy. Patients were 
randomly assigned to receive treatment with 
carbamazepine, gabapentin, lamotrigine, oxcarbazepine, 
or topiramate. The results showed that lamotrigine was a 
potential ﬁ rst-line treatment because it was signiﬁ cantly 
superior to carbamazepine for time to treatment failure 
(hazard ratio [HR] 0·78, 95% CI 0·63–0·97), but not 
signiﬁ cantly diﬀ erent to carbamazepine for time to 
12 months of remission. Gabapentin and topiramate 
were identiﬁ ed as unsuitable ﬁ rst-line treatments, 
gabapentin because of poor eﬃ  cacy and topiramate 
because of poor eﬃ  cacy and poor tolerability. 
Oxcarbazepine was not signiﬁ cantly diﬀ erent from 
carbamazepine for either outcome.
The epilepsies are a heterogeneous group of disorders, 
which consist of numerous seizure types2 and epilepsy 
syndromes3 with diﬀ ering causes, severities, and ages of 
onset. Although the SANAD results provide overall 
estimates of treatment eﬀ ect,1 a large heterogeneous group 
of patients was recruited, providing an opportunity to use 
prognostic modelling to investigate which clinical factors 
might aﬀ ect outcome. Previous prognostic models have 
been derived from the National General Practice Survey of 
Epilepsy,4 the Medical Research Council antiepileptic drug 
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withdrawal study,5 and the multicentre study of early 
epilepsy and single seizures.6 These models identiﬁ ed 
patient charac teristics that modify seizure recurrence risks, 
informing decisions about whether to stop antiepileptic 
drug treatment for patients with seizures in remission or 
whether to start antiepileptic drug treatment for patients 
with one or few seizures. However, few prognostic models 
based on data from prospective cohorts or randomised 
controlled trials have been published, and none represent 
an epilepsy cohort accrued at the start of antiepileptic drug 
treatment. In this Article we have modelled data from 
SANAD arm A to identify clinical factors that aﬀ ect 
outcome when antiepileptic drug treatment is started.
Methods
Patients and procedures
Patients were eligible for inclusion in arm A of the SANAD 
study if, in the previous year, they had had at least two 
clinically deﬁ nite unprovoked epileptic seizures, if they 
were at least 5 years old, and if the recruiting clinician 
deemed carbamazepine, not valproate, to be the optimum 
standard treatment. Between Dec 1, 1999, and June 1, 2001, 
patients were allocated in a ratio of 1:1:1:1 to receive 
carbamazepine, gabapentin, lamotrigine, or topiramate. 
From June 1, 2001, to Aug 31, 2004, an oxcarbazepine 
group was added to the trial and patients were randomly 
allocated in a ratio of 1:1:1:1:1 to receive carbamazepine, 
gabapentin, lamotrigine, oxcarbazepine, or topiramate.
SANAD had two primary outcomes. The ﬁ rst was time 
to treatment failure from randomisation. Treatment 
failure can be split into two categories: inadequate seizure 
control for which the randomly assigned drug might be 
withdrawn or a second treatment added, or failure 
because of unacceptable adverse events. Patients were 
categorised into these two main failure groups as was 
done in the original SANAD analyses.1,7 The second 
outcome was time to the ﬁ rst period of 12 months of 
remission from seizures. The methods for the SANAD 
study have been published in full.1
SANAD received appropriate multicentre research 
committee approvals, and was managed according to 
the Medical Research Council good clinical practice 
guidelines.8 Patients provided informed written consent 
for inclusion and long-term follow-up. SANAD is registered 
with the International Standard Randomized Controlled 
Trial Number Register, number ISRCTN38354748.
Prognostic modelling
Our aim was to identify two sets of factors—one that 
predicted time to 12 months of remission, and one that 
predicted time to treatment failure. On the basis of 
clinical consensus and our knowledge of previous 
prognostic studies in epilepsy,9,10 we compiled a list of 
potential prognostic factors: sex, febrile seizure history, 
ﬁ rst degree relative with epilepsy, CT or MRI scan results, 
treatment history, age, time from ﬁ rst seizure to 
randomisation, neurological insult (eg, hemiparesis), 
total number of seizures before randomisation, 
electroencephalogram (EEG) results, seizure type, and 
epilepsy type. For the CT and MRI scans, results were 
classiﬁ ed as normal, abnormal, or not done. Patients 
were classiﬁ ed as having had a neurological insult if 
they had learning disabilities or a neurological deﬁ cit. 
EEGs were classiﬁ ed as normal, not done, non-speciﬁ c 
378 allocated to receive carbamazepine
22 removed
      10 not epilepsy
        9 extremes*
        3 generalised†
7 missing outcome data
    1 for treatment failure
    6 for 12 month remission
355 analysed for treatment failure
350 analysed for 12 month remission
1836 patients assessed for eligibility
115 excluded (did not provide consent)
1721 randomly assigned
377 allocated to receive gabapentin
19 removed
      10 not epilepsy
        8 extremes*
        1 generalised†
9 missing outcome data
    2 for treatment failure
    7 for 12 month remission
356 analysed for treatment failure
351 analysed for 12 month remission
378 allocated to receive lamotrigine
20 removed
      8 not epilepsy
      7 extremes*
      5 generalised†
6 missing outcome data
    1 for treatment failure
    5 for 12 month remission
357 analysed for treatment failure
353 analysed for 12 month remission
210 allocated to receive oxcarbazepine
16 removed
      8 not epilepsy
      3 extremes*
      5 generalised†
3 missing outcome data
    1 for treatment failure
    2 for 12 month remission
193 analysed for treatment failure
192 analysed for 12 month remission
378 allocated to receive topiramate
24 removed
      8 not epilepsy
      7 extremes*
      9 generalised†
19 missing outcome data
        7 for treatment failure
      12 for 12 month remission
347 analysed for treatment failure
342 analysed for 12 month remission
Figure 1: Trial proﬁ le
*Patients with a time from ﬁ rst seizure to randomisation in the ﬁ rst or last 1% of the variable were removed from the data set.21 †Patients with generalised epilepsy were removed from analyses.
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abnormality, or epileptiform abnor mality (focal or 
generalised spikes or spike and slow wave activity).
Seizure types were classiﬁ ed according to the Inter-
national League Against Epilepsy seizure classiﬁ cation.2 
Epilepsy type was ﬁ rst classiﬁ ed as focal, generalised, or 
unclassiﬁ ed. When there was uncertainty between focal 
onset and generalised onset seizures, patients were 
recorded as having had unclassiﬁ ed convulsive or other 
unclassiﬁ ed seizures. Focal epilepsy was further classiﬁ ed 
as temporal lobe, frontal lobe, parietal lobe, occipital lobe, 
benign focal epilepsy, or focal epilepsy not localised. For 
the regression modelling, because of the small numbers 
of participants, occipital lobe, parietal lobe, and benign 
focal epilepsy were combined into one group (“other”). 
Only 29 patients were classiﬁ ed as having generalised 
epilepsy; hence, they were removed from the dataset.
Variables associated with an increased chance of 
treatment failure and an increased chance of achieving 
12 months of remission were determined after adjust ment 
for multiple variables with Cox proportional hazards 
modelling. Because oxcarbazepine was included only after 
June 1, 2001, all analyses were stratiﬁ ed by randomisation 
period to account for the reduced number of patients who 
took this drug. Variables were centred to reduce multi-
colinearity11 and tested with the likelihood ratio test.12 Best-
ﬁ tting, parsimonious, multivariable models were produced 
with backwards elimination. From the multivariable 
model we calculated the probability of the event for 
combinations of risk factors of age, sex, and total number 
of seizures. The proportional hazards assumption was 
tested with Schoenfeld residual plots13 and in corporation 
of time-dependent covariate eﬀ ects. Internal validity was 
Carbamazepine 
(n=355)
Gabapentin 
(n=356)
Lamotrigine 
(n=357)
Oxacarbaepine 
(n=193)
Topiramate 
(n=347)
Total 
(n=1608)
Males 196 (55%) 197 (55%) 199 (56%) 102 (53%) 193 (56%) 887 (55%)
History of febrile seizures 24 (7%) 15 (4%) 22 (6%) 7 (4%) 13 (4%) 81 (5%)
First degree relative with epilepsy 36 (10%) 41 (12%) 33 (9%) 21 (11%) 34 (10%) 165 (10%)
Treatment history
Treatment naive 290 (82%) 289 (81%) 292 (82%) 167 (87%) 282 (81%) 1320 (82%)
Taking non-SANAD antiepileptic drug* 57 (16%) 56 (16%) 58 (16%) 23 (12%) 57 (16%) 251 (16%)
Seizures after remission 8 (2%) 11 (3%) 7 (2%) 2 (1%) 9 (3%) 37 (2%)
Age at randomisation (years; median [IQR]) 38 (25–53) 36 (24– 50) 34 (22–51) 40 (27–56) 37 (25–52) 38 (24–52)
Time from ﬁ rst seizure to randomisation 
(years; median [IQR])
1·4 (0·5–4·9) 1·3 (0·6–6·0) 1·4 (0·5–4·7) 1·3 (0·5–4·0) 1·4 (0·5–5·3) 1·4 (0·5–5·1)
Neurological insult 42 (12%) 41 (12%) 41 (11%) 16 (8%) 43 (12%) 113 (7%)
Total seizures before randomisation 
(median [IQR])
12 (4–75) 14 (4–70) 12 (4–60) 11 (4–53) 12 (4–100) 12 (4–70)
Seizure type
Simple or complex partial only 122 (34%) 112 (31%) 105 (29%) 55 (28%) 116 (33%) 510 (32%)
Secondary generalised tonic-clonic 202 (57%) 209 (59%) 216 (61%) 117 (61%) 193 (56%) 937 (58%)
Uncertain 31 (9%) 35 (10%) 36 (10%) 21 (11%) 38 (11%) 161 (10%)
Epilepsy type
Focal 325 (92%) 323 (91%) 321 (90%) 173 (90%) 311 (90%) 1453 (90%)
Temporal 150 (46%) 120 (37%) 107 (33%) 56 (32%) 114 (37%) 547 (38%)
Frontal 20 (6%) 17 (5%) 34 (11%) 5 (3%) 31 (10%) 107 (7%)
Other 20 (6%) 28 (9%) 17 (5%) 13 (8%) 21 (6%) 99 (7%)
Not localised 135 (42%) 158 (49%) 163 (51%) 99 (57%) 145 (47%) 700 (48%)
Unclassiﬁ ed 30 (8%) 33 (9%) 36 (10%) 20 (10%) 36 (10%) 155 (10%)
EEG results
Normal 150 (42%) 177 (50%) 169 (47%) 84 (44%) 144 (41%) 724 (45%)
Non-speciﬁ c abnormality 59 (17%) 48 (13%) 56 (16%) 32 (17%) 59 (17%) 254 (16%)
Epileptiform abnormality 113 (32%) 100 (28%) 100 (28%) 54 (28%) 104 (30%) 471 (29%)
Not done 33 (9%) 31 (9%) 32 (9%) 23 (12%) 40 (12%) 159 (10%)
CT or MRI results
Normal 205 (58%) 225 (63%) 207 (58%) 109 (56%) 188 (54%) 934 (58%)
Abnormal 99 (28%) 82 (23%) 83 (23%) 53 (27%) 103 (30%) 420 (26%)
Not done 51 (14%) 49 (14%) 67 (19%) 31 (16%) 56 (16%) 254 (16%)
Data are n (%), unless otherwise stated. EEG=electroencephalogram. SANAD=Standard and New Antiepileptic Drug trial. *Antiepileptic drugs other than those that were 
randomly allocated in SANAD.
Table 1: Baseline characteristics of patients included in the analysis of time to treatment failure
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assessed by the c statistic, which assesses the dis-
criminatory power and the predictive accuracy of nonlinear 
statistical models.14
Assessment of the diﬀ erent reasons for treatment 
withdrawal requires a competing risks analysis that 
includes the probability of one of several diﬀ erent events 
occurring. Therefore, we did cumulative incidence 
analyses to assess the probability of one of the two treat-
ment failure events occurring (inadequate seizure control 
and unacceptable adverse events), with covariates tested 
by Gray’s method.15
We investigated continuous variables with log and 
fractional polynomial transformations.16–19 The results for 
the continuous variables are presented as categorical 
variables deﬁ ned post hoc with categories chosen 
according to knot positions for a spline model ﬁ t to the 
data.20 The time from ﬁ rst seizure to randomisation 
includes extreme values. Therefore people with a time 
from ﬁ rst seizure to randomisation in the ﬁ rst or last 1% 
of the variable were removed from the dataset21—this 
applied to 34 patients.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Figure 1 shows the ﬂ ow of the 1721 patients recruited into 
arm A of SANAD. 1608 patients were included in the 
analysis of time to treatment failure and 1588 were 
included in the analysis of time to 12 months of remission. 
The baseline demographic data for patients included in 
the analysis of time to treatment failure are summarised 
in table 1. Data were much the same for time to 12 months 
of remission (data not shown).
The parsimonious model for overall treatment failure 
included variables for sex, treatment history, age, total 
number of seizures before randomisation, EEG result, 
seizure type, focal epilepsy site of onset, and treatment, 
which was forced in the model regardless of signiﬁ cance, 
using the backward elimination process. Table 2 shows 
the multivariable HRs (see appendix for regression 
coeﬃ  cients and standard errors); HR greater 
than 1 indicates that treatment failure is more likely. The 
c statistic for the model was 0·6, indicating that the model 
accurately discriminates patients 60% of the time. 
Because the aim is to predict patients with poor outcomes, 
our c statistic suggests that the internal validation of the 
model is acceptable.
Treatment failure decreased as age increased and 
patients aged 10 years or younger were signiﬁ cantly 
more likely to have treatment failure. Treatment failure 
increased as the total number of seizures before 
randomisation increased and patients with two or fewer 
seizures before randomisation were signiﬁ cantly less 
likely to experience treatment failure. Treatment failure 
was signiﬁ cantly more likely in women than in men, in 
patients taking a non-SANAD antiepileptic drug (ie, not 
carbamazepine, gabapentin, lamotrigine, oxcarbazepine, 
Overall HR 
(95% CI)
Inadequate seizure 
control HR (95% CI)
Unacceptable adverse 
events HR (95% CI)
Sex
Female 1·00 1·00 1·00
Male 0·86 (0·75–0·99) 1·06 (0·86–1·31) 0·81 (0·66–0·98)
Treatment history
Treatment naive 1·00 1·00 1·00
Seizures after remission 1·35 (0·87–2·10) 0·48 (0·19–1·23) 2·13 (1·22–3·73)
Taking non-SANAD antiepileptic drugs 1·27 (1·05–1·53) 1·56 (1·20–2·03) 1·00 (0·75–1·33)
Age (years)
≤10 1·00 1·00 1·00
11–24 0·95 (0·91–0.99) 0·85 (0·79–0·90) 1·06 (1·00–1·12)
25–36 0·88 (0·80–0·97) 0·68 (0·58–0·78) 1·14 (1·01–1·30)
37–49 0·82 (0·71–0·96) 0·55 (0·44–0·69) 1·23 (1·01–1·49)
50–70 0·76 (0·61–0·94) 0·42 (0·30–0·58) 1·35 (1·02–1·79)
≥71 0·68 (0·51–0·91) 0·31 (0·19–0·48) 1·50 (1·02–2·20)
Total number of seizures before randomisation
≤2 1·00 1·00 1·00
3 1·02 (1·01–1·03) 1·04 (1·03–1·05) 1·00 (0·99–1·01)
4–11 1·08 (1·05–1·11) 1·14 (1·09–1·18) 0·99 (0·95–1·04)
12–50 1·17 (1·10–1·23) 1·29 (1·19–1·39) 0·99 (0·91–1·07)
51–299 1·28 (1·17–1·40) 1·51 (1·33–1·71) 0·98 (0·86–1·12)
≥300 1·52 (1·31–1·76) 2·00 (1·62–2·47) 0·97 (0·77–1·21)
EEG result
Normal 1·00 1·00 1·00
Not done 1·25 (0·96–1·61) 0·79 (0·51–1·22) 1·34 (0·95–1·88)
Non-speciﬁ c abnormality 1·20 (0·98–1·47) 1·01 (0·74–1·38) 1·21 (0·91–1·61)
Epileptiform abnormality 1·26 (1·07–1·50) 1·21 (0·94–1·55) 1·11 (0·87–1·41)
Seizure type
Simple or complex partial only 1·00 1·00 1·00
Secondary generalised tonic-clonic 0·78 (0·66–0·91) 1·01 (0·79–1·28) 0·69 (0·55–0·86)
Uncertain 0·33 (0·05–2·37) 0·76 (0·08–7·29) Could not be estimated
Focal epilepsy site of onset
Temporal 1·00 1·00 1·00
Not localised 1·25 (1·06–1·47) 1·18 (0·92–1·51) 1·17 (0·93–1·48)
Frontal 1·18 (0·88–1·58) 1·04 (0·69–1·59) 1·24 (0·81–1·90)
Other 0·92 (0·66–1·28) 1·04 (0·66–1·66) 0·76 (0·45–1·26)
Unclassiﬁ ed 2·69 (0·37–19·74) 1·28 (0·13–12·72) Could not be estimated
Treatment
Carbamazepine 1·00 1·00 1·00
Gabapentin 1·23 (1·00–1·51) 2·45 (1·80–3·34) 0·59 (0·43–0·80)
Lamotrigine 0·76 (0·61–0·95) 1·05 (0·75–1·48) 0·62 (0·46–0·85)
Oxcarbazepine 0·94 (0·72–1·23) 1·12 (0·73–1·73) 0·84 (0·59–1·20)
Topiramate 1·23 (1·00–1·52) 1·44 (1·03–2·00) 1·01 (0·77–1·32)
HR=hazard ratio. SANAD=Standard and New Antiepileptic Drug. EEG=electroencephalogram.
Table 2: Multivariable model hazard ratios for time to overall treatment failure, treatment failure 
because of inadequate seizure control, and treatment failure because of unacceptable adverse events, 
by prognostic factor
See Online for appendix
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or topiramate) immediately before randomisation than 
in patients who were treatment naive, in patients with 
an epileptiform EEG abnormality than in patients with 
a normal EEG, in patients with simple or complex 
partial seizures without secondary generalisation than 
in patients with secondary gener alised tonic-clonic 
seizures, in patients with epilepsy that was not localised 
than in patients with temporal lobe epilepsy, and in 
patients taking carbamazepine than in patients taking 
lamotrigine (table 2). To show the range of treatment 
failure rates predicted by the multivariable model, 
ﬁ gure 2 shows estimates of the proportion of patients 
treated with either carbamazepine or lamotrigine having 
treatment failure 1 year and 3 years after randomisation 
(see appendix for numerical results). 1 year and 3 years 
were chosen to represent medium-term and long-term 
timepoints. Patients were assumed to be treatment 
naive and to have normal EEG results, simple or 
complex partial seizures, and temporal lobe epilepsy, 
which were the most common characteristics in the 
SANAD dataset. The other variables were altered 
according to categories of interest (eg, age as 10 years, 
40 years, and 75 years; ﬁ gure 2). Lamotrigine and 
carbamazepine were chosen because carbamazepine is 
the standard treatment for focal epilepsy and lamotrigine 
was suggested by the results of the SANAD trial as a 
potential ﬁ rst line treatment after the publication of the 
initial results of SANAD. Generally, overall treatment 
failure rates were lower in patients treated with 
lamotrigine (ﬁ gure 2). The risk of failure decreased 
slightly with an increase in age and men had a slightly 
lower chance of treatment failure than did women. An 
increase in total number of seizures before 
randomisation also slightly increased the chance of 
treatment failure.
The competing risks model has been ﬁ tted to match the 
model for overall time to treatment failure results 
(table 2). The appendix includes regression coeﬃ   cients 
and results for the multivariable model including all 
variables—ie, without variable selection.
The signiﬁ cant variables in the model for treatment 
failure because of inadequate seizure control were 
treatment history, age, total number of seizures before 
randomisation, and treatment. Compared with treat ment 
naive patients, patients already taking a non-SANAD 
antiepileptic drug had a high rate of treatment failure 
because of inadequate seizure control (table 2). 
Figure 3 shows relative hazard plots for the continuous 
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Age (years) Sex  Seizures (n) Treatment    
Treatment failure at 1 year (%)
100804020 600
Treatment failure at 3 years (%)
100804020 600
Figure 2: Combination of risk factors for time to treatment failure
Bars show 95% CIs. M=male. F=female.
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variables (for associated regression coeﬃ  cients, see 
appendix). A linear eﬀ ect was noted for age, with older 
patients signiﬁ cantly less likely to have a treatment 
failure because of inadequate seizure control than were 
younger patients. The number of seizures before random-
isation was positively associated with the overall risk of 
treatment failure, which was largely caused by an 
increasing chance of failure because of inadequate 
seizure control.
The signiﬁ cant variables in the model of treatment 
failure because of unacceptable adverse events were sex, 
treatment history, age, seizure type, and treatment 
(table 2). Women were more likely to have treatment 
failure than were men. Patients restarting treatment after 
remission had a higher treatment failure rate than 
treatment naive patients. A linear eﬀ ect was noted for 
age, with older patients signiﬁ cantly more likely to have a 
treatment failure because of unacceptable adverse events 
than were younger patients (ﬁ gure 3). Patients with 
simple or complex partial seizures were signiﬁ cantly 
more likely to have a treatment failure attributable to 
adverse events than were patients with secondary 
generalised tonic-clonic seizures (table 2).
Although the chance of treatment failure for any reason 
decreased with age, in the competing risks analysis an 
X-shaped relation was seen (ﬁ gure 3), in which younger 
patients have a higher chance of treatment failure 
because of inadequate seizure control and a lower chance 
of treatment failure because of adverse events than do 
older patients, who have a lower chance of treatment 
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Figure 3: Relative hazard ratio plots for age and total number of seizures before randomisation for the time to treatment failure
Hazard ratio estimates with 95% CIs are shown for overall time to treatment failure, for age (A) and total number of seizures (B), and for time to treatment failure 
because of inadequate seizure control and because of unacceptable adverse events, for age (C) and total number of seizures (D).
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failure because of inadequate seizure control and a 
higher chance of treatment withdrawal because of 
unacceptable adverse events.
Table 3 and the appendix show results for time to 
12 months of remission. The factors signiﬁ cantly associated 
with time to 12 months of remission were sex, treatment 
history, age, time from ﬁ rst seizure to randomisation, 
neurological insult, total number of seizures before 
randomisation, CT or MRI scan results, and treatment. 
The c statistic for the model is 0·7, indicating that the 
model accurately discriminates patients 70% of the time, 
which is an acceptable internal validation.22,23
For age, the relation is U-shaped with patients aged 
10 years or less, or more than 71 years, having a 
signiﬁ cantly higher chance of remission than that of 
patients in the middle of the age range (ﬁ gure 4). Time 
to 12 months of remission was higher for men than for 
women, and for treatment naive patients than for 
patients already taking a non-SANAD antiepileptic drug 
(table 3). Time to 12 months of remission decreased with 
increasing number of seizures before randomisation 
(ﬁ gure 4, table 3). Figure 4 shows relative hazard plots 
for the continuous variables (for associated regression 
coeﬃ   cients, see appendix). Rates of 12 months of 
remission were signiﬁ cantly higher for patients on 
carbamazepine than for those on gabapentin or 
topiramate (table 3). To show the range of rates of 
12 months of remission predicted by the model, 
ﬁ gure 5 shows estimates of the proportion of patients 
achieving a remission 1 year and 3 years after 
randomisation for patients treated with either 
carbamazepine or lamotrigine (see appendix for 
numerical results). Patients were assumed to be treat-
ment naive, to have been randomised 6 months after 
their ﬁ rst seizure, to not have neurological insult, to have 
normal CT or MRI results, and to have temporal lobe 
epilepsy, because those were the most common patient 
characteristics. In the subset of combinations included, 
remission rates were highest in older patients. Men were 
slightly more likely to achieve remission than were 
women, as were patients with fewer seizures compared 
with patients with many seizures. The probability of 
remission in patients taking carbamazepine increased 
slightly compared with those taking lamotrigine, but not 
all the comparisons were signiﬁ cant.
Discussion
Treatment failure because of unacceptable adverse eﬀ ects 
was signiﬁ cantly less likely in men than in women, but 
no signiﬁ cant diﬀ erence existed for failure because of 
inadequate seizure control. This ﬁ nding could explain 
the lower time to 12 months of remission in women, if 
women are less likely to remain on treatment for long 
enough to achieve therapeutic doses. Further analyses of 
dose data in SANAD show no diﬀ erence between the 
mean doses of carbamazepine, oxcarbazepine, or 
topiramate taken by men and women, but women did 
receive lower doses of gabapentin and lamotrigine (data 
not shown). Baseline bodyweight was not measured in 
SANAD and therefore cannot be adjusted for.
Time to 12 months of remission HR (95% CI)
Sex
Female 1·00
Male 1·19 (1·05–1·35)
CT or MRI scan result
Normal 1·00
Abnormal 0·88 (0·76–1·03)
Not done 1·12 (0·93–1·34)
Treatment history
Treatment naive 1·00
Seizures after remission 1·06 (0·70–1·61)
Taking a non-SANAD antiepileptic drug 0·64 (0·52–0·78)
Age (years) 
≤10 1·00
11–24 0·88 (0·79–0·97)
25–36 0·82 (0·68–0·99)
37–49 0·85 (0·68–1·07)
50–70 1·07 (0·86–1·34)
≥71 1·60 (1·26–2·03)
Time from ﬁ rst seizure (months) 
≤2 1·00
3–5 1·00 (1·00–1·01)
6–17 1·01 (1·00–1·02)
18–59 1·03 (1·00–1·07)
60–239 1·14 (1·01–1·29)
≥240 1·39 (1·04–1·86)
Neurological insult
Absent 1·00
Present 0·75 (0·61–0·93)
Total number of seizures 
≤2 1·00
3 0·96 (0·95–0·97)
4–11 0·87 (0·85–0·90)
12–50 0·76 (0·72–0·81)
51–299 0·65 (0·59–0·71)
≥300 0·48 (0·41–0·56)
Focal epilepsy site of onset
Temporal 1·00
Not localised 0·87 (0·75–1·02)
Frontal 1·12 (0·86–1·45)
Other 1·02 (0·78–1·34)
Unclassiﬁ ed 1·15 (0·87–1·44)
Treatment
Carbamazepine 1·00
Gabapentin 0·71 (0·59–0·86)
Lamotrigine 0·90 (0·75–1·08)
Oxcarbazepine 0·97 (0·77–1·22)
Topiramate 0·81 (0·68–0·98)
HR=hazard ratio. 
Table 3: Multivariable model hazard ratios for prognostic factors for time to 12 months of remission
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Patients with an abnormal EEG were more likely to 
experience treatment failure than were those with a 
normal EEG, predominantly because of inadequate 
seizure control. Patients who did not have an EEG done 
had a lower chance of treatment failure because of 
inadequate seizure control and a higher chance of failure 
because of unacceptable adverse events. Patients who did 
not have an EEG tended to be older (mean age 42 years vs 
38 years) and therefore there might have been more 
clinical certainty that they had focal epilepsy.
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Figure 4: Relative hazard ratio plots for age, time from ﬁ rst seizure to randomisation, and total number of seizures for time to 12 months of remission
Hazard ratio estimates with 95% CIs are shown for time to 12 months of remission, for age (A), time from ﬁ rst seizure (B), and total number of seizures (C).
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Figure 5: Combination of risk factors for time to 12 months of remission
Bars show 95% CIs. M=male. F=female.
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Men were more likely to achieve 12 months of remission 
than were women, which might be because women had a 
higher rate of treatment withdrawal because of adverse 
events, which precedes a change in treatment and a delay 
in controlling seizures.
The relation between age and 12 months of remission is 
U-shaped—the chance of 12 months of remission is higher 
in children and elderly people than in those in the mid-age 
range (approximately 20–50 years old). This relation might 
be because of the diﬀ erent aetiologies in diﬀ erent age 
groups, pharmacokinetics, or other factors, and should be 
investigated further. As might be anticipated, patients who 
were already taking an anti epileptic drug but needed to 
change treatment had a lower chance of having 12 months 
of remission than did treatment naive patients. The chance 
of remission that lasted 12 months increased with time 
between ﬁ rst seizure and randomisation but decreased 
with increasing number of seizures before randomisation, 
indicating that patients with a larger number of seizures 
over a shorter period before starting treatment had a 
reduced chance of remission. Of the antiepileptic drugs, 
carbamazepine was associated with the highest rates of 
remission that lasted for 12 months.
The SANAD study is the largest randomised controlled 
trial in epilepsy and includes data for long-term treatment 
outcomes, which is essential to inform the management 
of this chronic condition (panel). A heterogeneous group 
of patients was recruited, which some have criticised26,27 
but we argue that this is a strength, as shown by this 
Article, because such a group enables thorough 
investigation of the factors that aﬀ ect treatment outcome; 
the multivariable models in this Article include up to 
nine clinical factors. The SANAD investigators were not 
masked to treatment allocation, which could have 
aﬀ ected outcome assess ment—for example, decisions 
about whether a treatment had failed—although dosing 
data indicate that reasonable doses were tried to give 
each treatment the best chance before it was decided 
that treatment had failed. Although randomised 
controlled trials are the best method for assessing 
treatment outcomes, they recruit a selected population, 
which might aﬀ ect estimates of prognosis. Ideally 
SANAD would have recruited a greater proportion of 
children and elderly patients; nonetheless, the analysis 
has clearly shown the eﬀ ect of age on outcome. 
Participants were predominantly examined by 
neurologists experienced at identifying and classifying 
seizures, but a further challenge in outpatient studies of 
seizures and epilepsy, such as SANAD, is that seizures 
are reported to the clinician by the patient, and patients 
might under-report the occurrence of seizures. Validation 
of patient reporting in an outpatient population with 
infrequent seizures is diﬃ  cult and has not been done to 
date. Recruiting clinicians were asked to estimate the 
likely site of seizure onset or if uncertain they were able 
to categorise the patient as such. This approach might 
lead to some imprecision, although it does allow patients 
to be categorised in a way that clinicians are familiar 
with and allows assessment of whether this categorisation 
is of prognostic value.
We have presented models that have the potential to 
inform patient counselling and treatment decisions, 
and internal validation of our two models suggests an 
adequate model ﬁ t. However, these models should be 
validated in other similar datasets and their predictive 
power should be tested. Unfortunately, no other datasets 
that are similar to SANAD exist. The best match is a set 
of individual participant data we have collected.28 
However, these data do not include covariates that are 
signiﬁ cant in the multivariable model and the treatments 
to which patients were randomly allocated do not always 
coincide with the drugs tested in SANAD. Therefore 
more work should be done to determine how best to 
overcome these diﬃ  culties.
Our results show the heterogeneity of outcome in 
epilepsy and the complex interplay between the factors 
that aﬀ ect the condition. Patients with diﬀ erent risks of 
treatment failure and achieving 12 months of remission 
could be identiﬁ ed when antiepileptic drug treatment is 
initiated. If validated, our results might improve 
predictions of outcome for patients and enable 
identiﬁ cation of patients more likely to have a poor 
treatment outcome, who might need to be followed up 
more regularly. The models might also help with identi-
ﬁ cation of patients with poor seizure control outcomes 
who might be eligible to participate in trials of new 
treatments, particularly treatments that might have a 
greater risk of adverse events than do conventional 
antiepileptic drugs, such as anti-inﬂ ammatory and 
other potential disease-modifying treatments.
Panel: Research in context
Systematic review
We identiﬁ ed studies published between Dec 1, 1946, and Jan 20, 2012, by searching 
Medline with the terms “prognostic model”, “prognostic factor”, “predictive model”, 
“predictive factor”, “epilepsy”, and “seizures”. Searches were restricted to human studies. 
Any prognostic factor studies or prognostic models reporting a seizure outcome were 
included. All included clinical trials were assessed by LB for methodological quality for 
randomisation, masking, and proportion of patients lost to follow-up.
Interpretation
Although other prognostic models have been constructed for epilepsy9,24,25 no other 
epilepsy monotherapy trial has had suﬃ  cient power to investigate prognostic factors 
thoroughly.6 Analysis of the National General Practice Study of Epilepsy4—a large 
prospective population-based observational study—identiﬁ ed only one independent 
predictor of 1 year and 2 year remission: the number of seizures the patient had had in the 
6 months after the ﬁ rst seizure. However, many patients in the National General Practice 
Study of Epilepsy were not prescribed antiepileptic drugs. Our Article extends previous 
studies because it is a thorough investigation of prognostic factors with data from a large 
randomised controlled trial in which patients were prescribed antiepileptic drugs. We have 
identiﬁ ed numerous prognostic factors for treatment failure and 12 months of remission 
from seizures and have produced models that should enable the estimation of these 
outcomes for individual patients.
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Although we have identiﬁ ed clinical predictors of 
outcome, the mechanism by which these factors 
aﬀ ect outcome are still poorly understood and some 
variability is unexplained. Personalised medicine and 
pharmacogenetics hold much interest and predictors of 
rare hypersensitivity reactions have been identiﬁ ed,29 but 
predictors of seizure control or common adverse eﬀ ects 
have not yet been established.
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